This study is looking at whether a treatment called emapalumab can help children and young adults (ages 0-25) with severe aplastic anemia (sAA). Aplastic anemia is a rare condition where your body stops producing enough new blood cells. Emapalumab works by blocking a protein called interferon gamma (IFNγ). The study aims to see if using emapalumab early can improve how well standard treatments work. To join, you would need to have suspected newly diagnosed sAA with low blood counts (cytopenias) and a bone marrow that doesn't have enough blood-forming cells (hypocellular marrow). Researchers will measure the best response to treatment after 6 weeks. The study plans to enroll 35 participants, but its current status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 35 participants, but the phase of the study is not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, "Best Response," is measured at 6 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.